Navigation Links
Chemistry turns killer gas into potential cure

Despite its deadly reputation, the gas carbon monoxide (CO) could actually save lives and boost health in future as a result of leading-edge UK research.

Chemists at the University of Sheffield have discovered an innovative way of using targeted small doses of CO which could benefit patients who have undergone heart surgery or organ transplants and people suffering from high blood pressure.

Although the gas is lethal in large doses, small amounts can reduce inflammation, widen blood vessels, increase blood flow, prevent unwanted blood clotting and even suppress the activity of cells and macrophages* which attack transplanted organs. The researchers have developed innovative water-soluble molecules which, when swallowed or injected, safely release small amounts of CO inside the human body.

Research carried out in the last decade had already highlighted possible advantages, as CO is produced in the body as part of its own natural defensive systems. However, the problem has been finding a safe way of delivering the right dose of CO to the patient. Conventional CO inhalation can run the risk of patients or medical staff being accidentally exposed to high doses. Now for the first time, thanks to chemistry, an answer appears to have been found.

The new CO-releasing molecules (CO-RMs) have been developed in partnership with Dr Roberto Motterlini at Northwick Park Institute for Medical Research (NPIMR) and with funding from the Engineering and Physical Sciences Research Council (EPSRC).

The molecules dissolve in water, so they can be made available in an easy-to-ingest, liquid form that quickly passes into the bloodstream, says Professor Brian Mann, from the University's Department of Chemistry, who led the research. As well as making it simple to control how much CO is introduced into a patients body, it will be possible to refine the design of the molecules so that they target a particular place while leaving the rest of the body unaffected.

The CO-RMs consist of carbonyls** of metals such as ruthenium, iron and manganese which are routinely used in clinical treatments. They can be designed to release CO over a period of between 30 minutes and several hours, depending on what is required to treat a particular medical condition.

As well as boosting survival rates and cutting recovery times, the new molecules could ease pressure on hospital budgets by reducing the time that patients need to spend in hospital, for example after an operation. They could even help some patients to avoid going into hospital in the first place.

Professor Mann added: This project provides an excellent example of how non-biological sciences like chemistry can underpin important advances in healthcare.

hemoCORM Ltd, a spinout company set up in 2004 by the University of Sheffield and NPIMR, is now taking the research towards commercialisation. It is hoped that, after further development work, Phase 1 clinical trials can begin in around two years, with deployment in the healthcare sector potentially achievable in around five years.


Contact: Natasha Richardson
Engineering and Physical Sciences Research Council

Related biology news :

1. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
2. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
3. Male elephants woo females with precise chemistry
4. Computer-chemistry yields new insight into a puzzle of cell division
5. Precision biochemistry tracks DNA damage in fish
6. Smoking changes brain chemistry
7. Comments, experts and background on the 2006 Nobel Prize in chemistry
8. New brain-chemistry differences found in depressed women
9. Lack of enzyme turns fat cells into fat burners
10. Programmable cells: Engineer turns bacteria into living computers
11. Gene therapy turns off mutation linked to Parkinsons disease
Post Your Comments:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology: